In this trial we will employ a gold-standard randomized double-blind placebo-controlled trial design to determine whether combining FxCO2-laser with the traditional therapy of clobetasol propionate 0.05% ointment (combined treatment) as compared to FxCO2-laser and placebo ointment (FxCO2-laser only) will improve treatment response in women undergoing FxCO2-laser for vulvar lichen sclerosus.
|Effective start/end date
|7/1/21 → 6/30/24
- MedStar Health Research Institute (Mueller AGMT 6/23/22 // Mueller AGMT 6/23/22)
- Patty Brisben Foundation for Women's Sexual Health (Mueller AGMT 6/23/22 // Mueller AGMT 6/23/22)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.